Compare Southwest Airlines Co (LUV) vs Pfizer Inc (PFE) Price & Performance

Southwest Airlines (LUV) trades at $48.28, up 0.42% today, with a neutral technical signal and mixed earnings history. Recent Q1 2026 EPS missed expectations, but Q4 2025 and Q3 2025 beat. Financials show modest revenue growth to $28.06B in 2025, but net income margin is thin at 2.83%. Analyst consensus is mixed with 42% buy, 47% hold, and 11% sell ratings, and a $52.47 price target implies potential upside. Key news highlights Q2 2026 earnings due July 23, 2026, amid fuel cost volatility and travel demand resilience.

LUV presents a cautious opportunity with upside to the consensus target, supported by operational improvements and sector tailwinds, but risks from fuel price swings, execution challenges, and thin margins warrant careful monitoring. The stock's valuation at a P/E of 32.05 appears elevated relative to earnings growth, requiring strong future performance to justify current levels.

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.

The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.